GSK ovarian, womb cancer drug posts positive results in early trial

(Sharecast News) - GSK said its gynaecological cancer drug candidate had revealed positive results from early trials and would swiftly move to late-stage five clinical studies globally in the next few months. The company on Sunday said Mocertatug Rezetecan, known as Mo-Rez, shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.

Hesham Abdullah, GSK's global head of cancer research and development, said: "Treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates. With Mo-Rez we now have compelling evidence of a promising clinical profile."

Endometrial cancer affects 1.6 million women globally, with 417,000 new cases each year. Ovarian cancer affects 843,000 people, with 240,000 new cases annually.

Reporting by Frank Prenesti for Sharecast.com

See the latest RNS on Investegate